Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Shearer Website

Gene M. Shearer, Ph.D.

Selected Publications

1)  Vaccari M, Fenizia C, Ma ZM, Hryniewicz A, Boasso A, Doster MN, Miller CJ, Lindegardh N, Tarning J, Landay AL, Shearer GM, Franchini G.
Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.
AIDS Res. Hum. Retroviruses. 30: 355-62, 2014.
2)  Vaccari M, Boasso A, Fenizia C, Fuchs D, Hryniewicz A, Morgan T, Weiss D, Doster MN, Heraud JM, Shearer GM, Franchini G.
Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2",3"-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade.
J. Virol. 86: 108-13, 2012.
3)  Shearer GM, Boasso A.
Alloantigen-based AIDS vaccine: revisiting a "rightfully" discarded promising strategy.
F1000 Med Rep. 3: 12, 2011.
4)  Boasso A, Royle CM, Doumazos S, Aquino VN, Biasin M, Piacentini L, Tavano B, Fuchs D, Mazzotta F, Lo Caputo S, Shearer GM, Clerici M, Graham DR.
Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis.
Blood. 118: 5152-62, 2011.
5)  Via CS, Shearer GM.
Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.
Autoimmunity. 43: 23-31, 2010.
6)  Kemp TJ, Hildesheim A, García-Piñeres A, Williams MC, Shearer GM, Rodriguez AC, Schiffman M, Burk R, Freer E, Bonilla J, Herrero R, Pinto LA.
Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection.
Cancer Epidemiol. Biomarkers Prev. 19: 1954-9, 2010.
7)  Biasin M, Piacentini L, Lo Caputo S, Naddeo V, Pierotti P, Borelli M, Trabattoni D, Mazzotta F, Shearer GM, Clerici M.
TLR activation pathways in HIV-1-exposed seronegative individuals.
J. Immunol. 184: 2710-7, 2010.
8)  Poirier MC, Olivero OA, Hardy AW, Franchini G, Borojerdi JP, Walker VE, Walker DM, Shearer GM.
Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.
AIDS Res Ther. 6: 24, 2009.
9)  Boasso A, Vaccari M, Fuchs D, Hardy AW, Tsai WP, Tryniszewska E, Shearer GM, Franchini G.
Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.
J. Immunol. 182: 4313-20, 2009.
10)  Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Vaccari M, Cecchinato V, Valeri V, Franchini G, Andersson J, Shearer GM.
HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques.
AIDS. 23: 35-40, 2009.
11)  Boasso A, Shearer GM, Chougnet C.
Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?.
J. Intern. Med. 265: 78-96, 2009.
12)  Broliden K, Haase AT, Ahuja SK, Shearer GM, Andersson J.
Introduction: Back to basics: mucosal immunity and novel HIV vaccine concepts.
J. Intern. Med. 265: 5-17, 2009.
13)  Walker DM, Kajon AE, Torres SM, Carter MM, McCash CL, Swenberg JA, Upton PB, Hardy AW, Olivero OA, Shearer GM, Poirier MC, Walker VE.
WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.
Environ. Mol. Mutagen. 50: 460-72, 2009.
14)  Vaccari M, Boasso A, Ma Z, Cecchinato V, Venzon D, Doster MN, Tsai WP, Shearer GM, Fuchs D, Felber BK, Pavlakis GN, Miller CJ, Franchini G.
CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.
Mucosal Immunol. 1: 497-507, 2008.
15)  Boasso A, Shearer GM.
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.
Clin. Immunol. 126: 235-42, 2008.
16)  Cano OD, Neurauter G, Fuchs D, Shearer GM, Boasso A.
Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells.
Neurosci. Lett. 438: 22-5, 2008.
17)  Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM.
HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation.
PLoS ONE. 3: e2961, 2008.
18)  Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G.
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection.
J. Immunol. 180: 5439-47, 2008.
19)  Boasso A, Hardy AW, Landay AL, Martinson JL, Anderson SA, Dolan MJ, Clerici M, Shearer GM.
PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: Restricted expression of type I interferon receptor by CCR5-expressing leukocytes.
Clin Immunol. 129: 132-44, 2008.
20)  Boasso A, Shearer GM, Clerici M.
The hunt for an HIV vaccine: time to rethink recent failures.
Lancet. 371: 1897-8, 2008.
21)  Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM.
HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells.
Blood. 109: 3351-9, 2007.
22)  Hardy AW, Graham DR, Shearer GM, Herbeuval JP.
HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha.
Proc. Natl. Acad. Sci. U.S.A. 104: 17453-8, 2007.
23)  Herbeuval JP, Shearer GM.
HIV-1 immunopathogenesis: how good interferon turns bad.
Clin. Immunol. 123: 121-8, 2007.
24)  Boasso A, Shearer GM.
How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation.
Curr. Drug Metab. 8: 217-23, 2007.
25)  Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G.
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques.
J. Immunol. 178: 3492-504, 2007.
26)  Chougnet CA, Shearer GM.
Regulatory T Cells (T(reg)) and HIV/AIDS: Summary of the September 7-8, 2006 Workshop.
AIDS Res. Hum. Retroviruses. 23: 945-52, 2007.
27)  Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnet C.
Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.
J. Virol. 81: 11593-603, 2007.
28)  Herbeuval J, Shearer G.
Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?.
AIDS Rev. 8: 3-8, 2006.
29)  Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai W, Heraud J, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G.
CTLA-4 blockade decreases TGF-{beta}, indoleamine 2,3- dioxygenase, and viral RNA expression in tissues of SIVmac251-infected macaques.
Blood. 108: 3834-42, 2006.
30)  Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Kruhlak MJ, Anderson SA, Dolan MJ, Dy M, Andersson J, Shearer GM.
Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.
Proc. Natl. Acad. Sci. U.S.A. 103: 7000-5, 2006.
31)  Boasso A, Vaccari M, Nilsson J, Shearer GM, Andersson J, Cecchinato V, Chougnet C, Franchini G.
Do regulatory T-cells play a role in AIDS pathogenesis?.
AIDS Rev. 8: 141-7, 2006.
32)  Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, Shearer GM, Andersson J, Chougnet C.
HIV-1 driven regulatory T cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS.
Blood. 108: 3808-17, 2006.
33)  Bedoya VI, Boasso A, Hardy AW, Rybak S, Shearer GM, Rugeles MT.
Ribonucleases in HIV Type 1 Inhibition: Effect of Recombinant RNases on Infection of Primary T Cells and Immune Activation-Induced RNase Gene and Protein Expression.
AIDS Res. Hum. Retroviruses. 22: 897-907, 2006.
34)  Herbeuval J, Grivel J, Boasso A, Hardy AW, Chougnet C, Dolan MJ, Yagita H, Lifson JD, Shearer GM.
CD4+ T cell death induced by infectious and noninfectious HIV-1: role of type I interferon-dependent, TRAIL/DR5-mediated apoptosis.
Blood. 106: 3524-31, 2005.
35)  Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM.
Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.
Blood. 105: 1574-81, 2005.
36)  Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M, Shearer GM.
Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.
Proc. Natl. Acad. Sci. U.S.A. 102: 13974-9, 2005.
37)  Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, Shearer GM, Chougnet CA.
The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients.
J. Immunol. 174: 3143-7, 2005.
38)  Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, Chougnet C, Lifson JD, Shearer GM.
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells.
Blood. 105: 2458-64, 2005.
39)  Rugeles MT, Shearer GM.
Alloantigen recognition in utero: dual advantage for the fetus?.
Trends Immunol. 25: 348-52, 2004.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/11/2014.